Menu Search
Equities

Vericel Corp

VCEL:NMQ

Vericel Corp

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)59.72
  • Today's Change3.01 / 5.31%
  • Shares traded169.44k
  • 1 Year change+68.27%
  • Beta1.6854
Data delayed at least 15 minutes, as of Nov 22 2024 18:29 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
  • 21-Nov-24
Select bar for recommendation details.
Recommendations21-Nov-24
Buy4
Outperform4
Hold0
Sell0
Strong Sell0

Share price forecast in USD

The 8 analysts offering 12 month price targets for Vericel Corp have a median target of 60.00, with a high estimate of 65.00 and a low estimate of 56.00. The median estimate represents a 5.80% increase from the last price of 56.71.
High14.6%65.00
Med5.8%60.00
Low-1.3%56.00

Earnings history & estimates in USD

On Nov 07, 2024, Vericel Corp reported 3rd quarter 2024 losses of -0.02 per share. This result was in line with the consensus of the 7 analysts following the company and exceeded last year's 3rd quarter results by 75.00%.
The next earnings announcement is expected on Feb 26, 2025.
Average growth rate+27.50%
Vericel Corp reported annual 2023 losses of -0.07 per share on Feb 29, 2024.
Average growth rate-19.38%
More ▼

Revenue history & estimates in USD

Vericel Corporation had 3rd quarter 2024 revenues of 57.91m. This bettered the 55.20m consensus of the 7 analysts covering the company. This was 41.17% above the prior year's 3rd quarter results.
Average growth rate+8.54%
Vericel Corporation had revenues for the full year 2023 of 197.52m. This was 20.17% above the prior year's results.
Average growth rate+14.14%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.